<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24120" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Laxatives</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Anam</given-names>
          </name>
          <aff>West Virginia University-Charleston/CAMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anam Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24120.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Laxatives are a category of medications frequently used to address constipation and various other gastrointestinal medical conditions. Their primary mechanism involves enhancing digestion and promoting bowel movements, thereby facilitating the process of bodily excretion.&#x000a0;Laxatives can provide relief for patients with irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid-induced constipation. Besides addressing constipation, laxatives are occasionally used to empty the bowels before procedures such as colonoscopies. Osmotic or stimulant laxatives are typically used as the first treatment option for constipation. If they do not effectively manage constipation, prokinetics or secretagogues may be used as the next steps.&#x000a0;Laxatives are categorized based on the mechanism of action they exert, including bulk-forming laxatives, osmotic and prokinetic agents, lubricants, stimulants, and other types.&#x000a0;</p>
        <p>Notably, laxative therapy is not the sole treatment for constipation. Initial management should involve lifestyle changes, including consuming increased fluids and fiber-rich foods, such as asparagus, broccoli, Brussels sprouts, cabbage, and spinach, into their diet. If constipation persists despite lifestyle modifications, the use of laxatives becomes a viable consideration. The comprehensive approach to treating chronic constipation encompasses patient education, behavior modification, dietary adjustments, and, if necessary, the inclusion of laxative therapy.&#x000a0;This activity provides a comprehensive review of laxative classification,&#x000a0;mechanism of action, proper administration, monitoring practices, and contraindications necessary for healthcare providers to&#x000a0;proficiently address constipation and contribute to the overall well-being of their patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate laxative classification based on the patient's clinical presentation and underlying conditions to determine the most suitable option for individual patients.</p></list-item><list-item><p>Implement evidence-based guidelines for the effective and safe use of laxatives in managing constipation.</p></list-item><list-item><p>Assess patient response to laxative therapy, including first- and second-line agents, and adjust treatment plans as necessary.</p></list-item><list-item><p>Communicate effectively with patients and coordinate care by integrating lifestyle modifications, patient education, and behavioral interventions alongside laxative therapy for comprehensive and patient-centered outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24120&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24120">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24120.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Laxatives are a category of medications frequently used to address constipation and various other gastrointestinal medical conditions. Their primary mechanism involves enhancing digestion and promoting bowel movements, thereby facilitating the process of bodily excretion.&#x000a0;Osmotic or stimulant laxatives are typically used as the first treatment option for constipation. If they do not effectively manage constipation, prokinetics or secretagogues may be used as the next steps.<xref ref-type="bibr" rid="article-24120.r1">[1]</xref>&#x000a0;</p>
        <p>Laxatives can provide relief for patients with irritable bowel syndrome (IBS)&#x000a0;with constipation, chronic idiopathic constipation (CIC), and opioid-induced constipation.&#x000a0;Yasser Masri et al have described the prophylactic use of laxatives in intensive care unit (ICU) patients to prevent constipation.<xref ref-type="bibr" rid="article-24120.r2">[2]</xref>&#x000a0;Also, O'Brien et al have suggested laxatives during opioid&#x000a0;administration in patients with sickle cell disease, particularly in post-surgical&#x000a0;patients and younger children.<xref ref-type="bibr" rid="article-24120.r3">[3]</xref>&#x000a0;</p>
        <p>Constipation is a common diagnosis that requires proper evaluation and appropriate treatment. Notably, laxative therapy is not the sole treatment for constipation. Initial management should involve lifestyle changes, including consuming increased fluids and fiber-rich foods, such as asparagus, broccoli, Brussels sprouts, cabbage, and spinach, into their diet. If constipation persists despite lifestyle modifications, the use of laxatives becomes a viable consideration. The comprehensive approach to treating chronic constipation encompasses patient education, behavior modification, dietary adjustments, and, if necessary, the inclusion of laxative therapy.&#x000a0;</p>
        <p>In addition to alleviating constipation, laxatives are occasionally used to empty the bowels before procedures such as colonoscopies. According to the American Gastroenterological Association's 2023 guidelines, CIC is a common clinical condition affecting approximately 8% to 12% of the US population. Regarding pharmacological interventions, treatment options encompass a range of over-the-counter and prescription medications, such as polyethylene glycol (PEG),&#x000a0;magnesium oxide,&#x000a0;lactulose, and bisacodyl. Unresponsive CIC may require treatment with lubiprostone, linaclotide, plecanatide, or prokinetic agents.<xref ref-type="bibr" rid="article-24120.r4">[4]</xref></p>
      </sec>
      <sec id="article-24120.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Laxatives are categorized based on the mechanism of action they exert, as mentioned below.</p>
        <p><bold>Bulk-forming laxatives:</bold>&#x000a0;These agents retain fluid in the stool, increasing stool weight and consistency.<xref ref-type="bibr" rid="article-24120.r5">[5]</xref>&#x000a0;Psyllium, dietary fiber, and methylcellulose are common examples. It is important to take ample water for bulk-forming agents to work. Lack of water,&#x000a0;in turn,&#x000a0;can lead to bloating and cause bowel obstruction.<xref ref-type="bibr" rid="article-24120.r6">[6]</xref></p>
        <p><bold>Osmotic agents: </bold>This class of medicines is poorly absorbable and draws water into the lumen of the bowel.<xref ref-type="bibr" rid="article-24120.r5">[5]</xref>&#x000a0;Milk of magnesia, lactulose, sorbitol, and PEG are common examples.</p>
        <p><bold>Prokinetic agents: </bold>Cisapride and tegaserod work as agonists of 5-hydroxytryptamine receptors.<xref ref-type="bibr" rid="article-24120.r5">[5]</xref>&#x000a0;They work on intrinsic neurons,&#x000a0;releasing acetylcholine and inducing mucosal secretion.<xref ref-type="bibr" rid="article-24120.r7">[7]</xref>&#x000a0;However, cisapride has been withdrawn from the market due to concerns about severe cardiovascular adverse effects. Tegaserod&#x000a0;is available under new investigational drug processes.&#x000a0;Prucalopride is a selective, high-affinity 5-HT<sub>4</sub>&#x000a0;agonist.<xref ref-type="bibr" rid="article-24120.r8">[8]</xref> ATI-7505 and velusetrag are agents under investigation as well.<xref ref-type="bibr" rid="article-24120.r7">[7]</xref></p>
        <p><bold>Lubricants: </bold>Mineral oil aids the passage of stools by its lubricating action throughout the intestines.<xref ref-type="bibr" rid="article-24120.r9">[9]</xref></p>
        <p><bold>Stimulants:</bold>&#x000a0;Stimulate the myenteric&#x000a0;plexus and the Auerbach plexus, increasing intestinal secretions and motility.<xref ref-type="bibr" rid="article-24120.r10">[10]</xref>&#x000a0;They also decrease the absorption&#x000a0;of water from the lumen of the bowel.<xref ref-type="bibr" rid="article-24120.r6">[6]</xref>&#x000a0;Examples include Bisacodyl, senna, cascara, and sodium picosulfate (SPS). Senna and cascara are present in herbal teas or remedies.<xref ref-type="bibr" rid="article-24120.r5">[5]</xref></p>
        <p><bold>Surface active agents:</bold>&#x000a0;Docusate lowers the surface tension, which leads to water and fats&#x000a0;penetrating the stool.<xref ref-type="bibr" rid="article-24120.r11">[11]</xref></p>
        <p><bold>Guanylate cyclase agonist:</bold> Linaclotide induces cGMP, leading to cystic fibrosis transmembrane conductance regulator (CFTR), which, in turn, causes water and electrolyte secretion into the lumen.<xref ref-type="bibr" rid="article-24120.r12">[12]</xref>&#x000a0;Plecanatide is also an intestinal secretagogue acting through a similar mechanism.<xref ref-type="bibr" rid="article-24120.r4">[4]</xref></p>
        <p><bold>Chloride channel activator:</bold> Lubiprostone, a chloride channel activator, leads to water and chloride secretion into the stool and softer stool consistency.<xref ref-type="bibr" rid="article-24120.r12">[12]</xref></p>
        <p><bold>Peripherally acting mu-opioid receptor antagonists: </bold>These&#x000a0;drugs are used&#x000a0;in opioid-induced constipation&#x000a0;and block mu-opioid receptors in the gastrointestinal tract, restoring the function of the enteric nervous system without penetrating the central nervous system. Drugs in this category include naldemedine,&#x000a0;naloxegol, and&#x000a0;methylnatrexone.&#x000a0;The American Gastroenterological Association recommends traditional laxatives as first-line agents and endorses peripherally acting mu-opioid receptor antagonists (PAMORAs) for cases requiring escalation of therapy.<xref ref-type="bibr" rid="article-24120.r13">[13]</xref></p>
      </sec>
      <sec id="article-24120.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Laxatives are usually taken orally or as suppositories. Oral formulations include tablets, capsules, powders, chewable tablets, and liquids. Data presented in this section are from product labeling information.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Bulk-forming laxatives:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Psyllium: One tablespoon orally&#x000a0;1 to 3 times daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methylcellulose: One tablespoon powder or 2000 mg fiber caplets thrice daily.</p>
          </list-item>
        </list>
        <p>
<bold>Osmotic agents:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lactulose: For constipation, 10 to 20 g (15 to 30 mL) orally daily; the dose may be increased to 40 g (60 mL) daily.&#x000a0;For hepatic encephalopathy, 20 to 30 g (30 to 45 mL) orally every hour to induce rapid bowel movement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sorbitol: 30 to 150 mL orally daily. It can also be administered as a 120 mL (30%) solution rectal enema.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Polyethylene glycol: For constipation, 17&#x000a0;g with adequate&#x000a0;hydration. When used as bowel preparation before surgery, powder for solution (240 mL reconstituted solution) is given orally every 10 minutes until 4 L is consumed&#x000a0;and rectal effluent is clear. The patient should fast for at least 3 to 4 hours before administering PEG.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Magnesium sulfate: 2 to 4 teaspoons (approximately 10 to 20 g) of granules dissolved in 8 ounces (240 mL) of water; may repeat in 4 hours. Do not exceed&#x000a0;2 doses per day.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glycerin (glycerol): One suppository (2 or 3 g) per rectum for 15 minutes daily.</p>
          </list-item>
        </list>
        <p>
<bold>Stimulant laxatives:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bisacodyl: 5 to 15 mg as enteric oral tablets daily. Bisacodyl can also be administered as a 10 mg suppository per rectum one time per day for 15 to 60 minutes.&#x000a0;Several studies and review articles have raised concerns about the effectiveness of docusate in preventing constipation; clinical judgment should be based on response to therapy.<xref ref-type="bibr" rid="article-24120.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Senna: Available as an 8.6 mg tablet. Administer 1 to 2 tablets orally, 1 or&#x000a0;2 times per day.</p>
          </list-item>
        </list>
        <p>
<bold>Prokinetic agents:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tegaserod: Available as 6 mg oral tablets. One tablet is given orally 30 minutes before a meal twice daily for 4 to 6 weeks of treatment.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prucalopride: Available as 1 mg and 2 mg oral tablets. Administer&#x000a0;1 to&#x000a0;2 tablets orally daily.</p>
          </list-item>
        </list>
        <p>
<bold>Lubricants:&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mineral oil: Given in single or divided doses orally to 45 mL in 24 hours. It can also be administered&#x000a0;rectally as a single dose (118 mL).</p>
          </list-item>
        </list>
        <p>
<bold>Surface active agents:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Docusate: Available as 100 mg oral soft gels,&#x000a0;283 mg/5 mL (5 mL) of a rectal enema, and&#x000a0;50 mg/5 mL oral solution. It is given orally as a 50 to 100 mg dose daily to a maximum of 300 mg. In addition, it can be given rectally as 283 mg enema&#x000a0;1 to&#x000a0;3 times a day.&#x000a0;Several studies and review articles have raised doubts about the effectiveness of docusate in preventing constipation, with a systematic review concluding that docusate demonstrates no greater efficacy than a placebo.</p>
          </list-item>
        </list>
        <p>
<bold>Guanylate cyclase agonist:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Linaclotide: Available&#x000a0;in 72, 145, and 290 mcg oral capsules. A 72- to 145-mcg dosage is given to patients with&#x000a0;CIC daily. In patients with IBS with constipation, 290 mcg is used orally daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Plencatide: Available as a 3 mg tablet. The suggested dosage is 3 mg daily for IBS with constipation and CIC.<xref ref-type="bibr" rid="article-24120.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Chloride channel activator:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lubiprostone: Available in&#x000a0;8 mcg and 24 mcg oral capsules. For CIC, 8 mcg is given twice daily, and for opioid-induced constipation, a maximum of 24 mcg is used orally twice daily.</p>
          </list-item>
        </list>
        <p>
<bold>PAMORAs:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Naloxegol: Available in&#x000a0;12.5 and 25 mg tablets. The suggested dosage is&#x000a0;25 mg daily. Reduce dose to 12.5 mg daily in intolerance&#x000a0;due to&#x000a0;diarrhea&#x000a0;or abdominal pain.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methylnaltrexone: Available in&#x000a0;2 formulations - tablets and injections. The tablets&#x000a0;are in a single strength of 150 mg. The injections&#x000a0;are in varying concentrations and available in single-dose vials and pre-filled syringes. The single-dose vials contain 12 mg/0.6 mL of methylnaltrexone, while pre-filled syringes are available in&#x000a0;2 strengths - 8 mg/0.4 mL and 12 mg/0.6 mL. The recommended daily oral dosage for tablets is 450 mg.<xref ref-type="bibr" rid="article-24120.r15">[15]</xref>&#x000a0;The injectable form typically involves a subcutaneous administration of 12 mg daily. Additionally, weight-based dosing is advised for adult patients experiencing opioid-induced constipation with advanced illness.<xref ref-type="bibr" rid="article-24120.r16">[16]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Naldemedine: Available in 0.2 mg oral tablet. The recommended dose is 0.2 mg daily.<xref ref-type="bibr" rid="article-24120.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24120.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>While most laxatives are generally safe when used appropriately, they can have adverse effects, as mentioned below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Osmotic&#x000a0;agents like lactulose can have adverse effects like bloating, nausea, vomiting, and&#x000a0;diarrhea.<xref ref-type="bibr" rid="article-24120.r10">[10]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stimulant laxatives are known to&#x000a0;cause abdominal pain.<xref ref-type="bibr" rid="article-24120.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cisapride was withdrawn from the market after cardiovascular adverse effects, including prolonged QT interval that increases the risk for Torsades de Pointes.<xref ref-type="bibr" rid="article-24120.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mineral oil can cause aspiration and lipoid&#x000a0;pneumonia.<xref ref-type="bibr" rid="article-24120.r6">[6]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Osmotic agents like magnesium can cause metabolic disturbances, especially in the presence of&#x000a0;renal impairment. Magnesium excretion depends on renal function and requires caution in chronic kidney disease.<xref ref-type="bibr" rid="article-24120.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Osmotic agents result in volume load and&#x000a0;should&#x000a0;be used with caution in renal or cardiac dysfunction.<xref ref-type="bibr" rid="article-24120.r19">[19]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>With prokinetic agents, adverse effects like headache, nausea, and diarrhea have been described.<xref ref-type="bibr" rid="article-24120.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Secretagogues like linaclotide can occasionally cause diarrhea.<xref ref-type="bibr" rid="article-24120.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Long-term stimulant laxative use&#x000a0;is correlated with the loss of haustral folds in the colon; this could indicate neuronal or muscular injury caused by these agents.<xref ref-type="bibr" rid="article-24120.r20">[20]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In&#x000a0;vitro studies have described stimulant laxatives like senna and bisacodyl as having neoplastic potential, but data are lacking in human studies so far.<xref ref-type="bibr" rid="article-24120.r21">[21]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Naloxegol may lead to severe abdominal pain and diarrhea, necessitating hospitalization. Reported cases include gastrointestinal perforation. However, according to the literature, Naloxegol has a low level of causality with adverse events, including gastrointestinal perforation, seizures, stroke, cardiovascular mortality, and ventricular arrhythmia.<xref ref-type="bibr" rid="article-24120.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A cohort study utilized UK Biobank data to explore the relationship between regular laxative use and dementia incidence in&#x000a0;adults aged 40 to 69 without prior dementia history.&#x000a0;The study revealed that regular use of laxatives increases the risk of all-cause dementia.&#x000a0;Increased risk was notably observed among those using multiple or osmotic laxatives.<xref ref-type="bibr" rid="article-24120.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24120.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contraindications involved with laxatives are provided below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Generally, patients with hypersensitivity reactions to any active drug or excipients should avoid a particular medicine.<xref ref-type="bibr" rid="article-24120.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients should avoid laxatives during pregnancy, and bulk laxatives are considered safe during pregnancy. Stimulant laxatives are considered second-line.<xref ref-type="bibr" rid="article-24120.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Contraindications to bulk-forming agents include bedridden patients and those with altered cognition.<xref ref-type="bibr" rid="article-24120.r26">[26]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psyllium agents are contraindicated in those with allergic reactions.<xref ref-type="bibr" rid="article-24120.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Use lactulose cautiously in pediatric patients, debilitated patients, patients with hepatic impairment, and older patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sorbitol should be used with caution in patients with renal impairment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The use of Tegaserod is contraindicated in severe renal and hepatic impairment.<xref ref-type="bibr" rid="article-24120.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prucalopride is contraindicated in patients with intestinal obstruction or perforation, ulcerative colitis, Crohn disease, and toxic megacolon.<xref ref-type="bibr" rid="article-24120.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lubiprostone is contraindicated in patients with intestinal obstruction and patients with severe hepatic impairment.<xref ref-type="bibr" rid="article-24120.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The FDA has released a boxed warning for plecanatide. Avoid plecanatide in patients aged 6 or younger due to potential dehydration-related fatalities.<xref ref-type="bibr" rid="article-24120.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24120.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In the ongoing assessment of patients undergoing laxative therapy, it is essential to evaluate the therapeutic effectiveness or any potential failures regularly. Additionally, vigilant monitoring for fissures or hemorrhoids, often associated with chronic constipation, is crucial. Continuous monitoring of serum electrolyte levels is imperative for patients, particularly those with conditions predisposing them to electrolyte abnormalities, especially when using osmotic laxatives over an extended period.<xref ref-type="bibr" rid="article-24120.r31">[31]</xref></p>
        <p>The American Gastroenterological Association recommends monitoring the Bowel Function Index in patients experiencing opioid-induced constipation. This scoring system assists in identifying individuals who have not adequately responded to initial laxative treatments for opioid-induced constipation, signaling the need for therapy escalation.<xref ref-type="bibr" rid="article-24120.r13">[13]</xref></p>
      </sec>
      <sec id="article-24120.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Laxative abuse is not uncommon and is found in patients with anorexia nervosa or bulimia nervosa and older patients who continue to use laxatives once started for constipation. It also includes patients&#x000a0;with surreptitious&#x000a0;diarrhea.<xref ref-type="bibr" rid="article-24120.r32">[32]</xref>&#x000a0;Patients who misuse laxatives usually complain of diarrhea with alternating constipation, nausea, and vomiting.<xref ref-type="bibr" rid="article-24120.r33">[33]</xref>&#x000a0;</p>
        <p>These patients can present with dehydration and electrolyte imbalances like hyponatremia, hypokalemia, hyperuricemia, and hyperaldosteronism.<xref ref-type="bibr" rid="article-24120.r33">[33]</xref>&#x000a0;Dehydration and hypokalemia together can cause renal insufficiency.<xref ref-type="bibr" rid="article-24120.r34">[34]</xref>&#x000a0;In diarrhea, potassium and volume depletion increases aldosterone secretion,&#x000a0;worsening hypokalemia.<xref ref-type="bibr" rid="article-24120.r34">[34]</xref>&#x000a0;</p>
        <p>The treatment of laxative abuse is to quit the causative agent. The main challenges&#x000a0;are rebound symptoms&#x000a0;like weight gain, edema, and constipation, which are very distressing for the patient. Edema is due to renal retention of water. Diuretics should be used with caution to help with constipation and edema and increase patient tolerance when stopping laxative use. Renal function and electrolytes require careful monitoring. Diuretics can be tapered over&#x000a0;3 months.<xref ref-type="bibr" rid="article-24120.r35">[35]</xref></p>
      </sec>
      <sec id="article-24120.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Laxatives can effectively treat various medical conditions but may cause adverse effects such as abdominal pain, nausea, and urinary retention. Prescription guidelines for laxative use are crucial for clinicians, as constipation is highly prevalent in outpatient care and requires appropriate patient education.&#x000a0;<xref ref-type="bibr" rid="article-24120.r36">[36]</xref><xref ref-type="bibr" rid="article-24120.r4">[4]</xref>&#x000a0;Constipation&#x000a0;is prevalent in older patients when admitted inpatient and leads to prolonged hospital stays.</p>
        <p>Interprofessional healthcare providers, including clinicians, nurses, pharmacists, dieticians, and care staff, should work together to appropriately manage laxative use in patients. Various interventions include maintenance of stool charts, medication review, and medication compliance to manage&#x000a0;functional bowel movements during hospitalization.<xref ref-type="bibr" rid="article-24120.r37">[37]</xref> Pharmacists also play a role by reviewing medication management and communicating&#x000a0;any identified concerns to clinicians.&#x000a0;An interprofessional approach involving clinicians, gastroenterologists, pharmacists, and nurses can enhance patient outcomes while reducing the occurrence of adverse drug reactions.</p>
      </sec>
      <sec id="article-24120.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24120&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24120">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24120/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24120">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24120.s11">
        <title>References</title>
        <ref id="article-24120.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krogh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiarioni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Management of chronic constipation in adults.</article-title>
            <source>United European Gastroenterol J</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>465</fpage>
            <page-range>465-472</page-range>
            <pub-id pub-id-type="pmid">28588875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masri</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abubaker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic use of laxative for constipation in critically ill patients.</article-title>
            <source>Ann Thorac Med</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>228</fpage>
            <page-range>228-31</page-range>
            <pub-id pub-id-type="pmid">20981183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Brien</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelleher</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Inpatient use of laxatives during opioid administration in children with sickle cell disease.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>559</fpage>
            <page-range>559-62</page-range>
            <pub-id pub-id-type="pmid">20049931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chey</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Imdad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almario</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Bharucha</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Diem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Lembo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.</article-title>
            <source>Gastroenterology</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>164</volume>
            <issue>7</issue>
            <fpage>1086</fpage>
            <page-range>1086-1106</page-range>
            <pub-id pub-id-type="pmid">37211380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>Chronic constipation: current treatment options.</article-title>
            <source>Can J Gastroenterol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>25 Suppl B</volume>
            <issue>Suppl B</issue>
            <fpage>22B</fpage>
            <page-range>22B-28B</page-range>
            <pub-id pub-id-type="pmid">22114754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Riutta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosser</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Chronic constipation: an evidence-based review.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-51</page-range>
            <pub-id pub-id-type="pmid">21737769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bharucha</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Behavioural and new pharmacological treatments for constipation: getting the balance right.</article-title>
            <source>Gut</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>1288</fpage>
            <page-range>1288-96</page-range>
            <pub-id pub-id-type="pmid">20801775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prucalopride: A Recently Approved Drug by the Food and Drug Administration for Chronic Idiopathic Constipation.</article-title>
            <source>Int J Appl Basic Med Res</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-2</page-range>
            <pub-id pub-id-type="pmid">30820411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>JAMA patient page. Over-the-counter laxatives.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Sep</month>
            <day>17</day>
            <volume>312</volume>
            <issue>11</issue>
            <fpage>1167</fpage>
            <pub-id pub-id-type="pmid">25226492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Lissner</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of chronic constipation: current pharmacologic approaches and future directions.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2009</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <page-range>502-8; quiz 496</page-range>
            <pub-id pub-id-type="pmid">19138759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Twycross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mihalyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilcock</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Stimulant laxatives and opioid-induced constipation.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>306</fpage>
            <page-range>306-13</page-range>
            <pub-id pub-id-type="pmid">22248790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andresen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Layer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Medical Therapy of Constipation: Current Standards and Beyond.</article-title>
            <source>Visc Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-127</page-range>
            <pub-id pub-id-type="pmid">29888241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crockett</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <collab>American Gastroenterological Association Institute Clinical Guidelines Committee</collab>
            </person-group>
            <article-title>American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation.</article-title>
            <source>Gastroenterology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>218</fpage>
            <page-range>218-226</page-range>
            <pub-id pub-id-type="pmid">30340754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaiswal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Naz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Quinonez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pokhrel</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>A rare case of pediatric pancreatic pseudocyst.</article-title>
            <source>Clin Case Rep</source>
            <year>2022</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>e05879</fpage>
            <pub-id pub-id-type="pmid">35600019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Israel</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone.</article-title>
            <source>J Pain Res</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>2509</fpage>
            <page-range>2509-2516</page-range>
            <pub-id pub-id-type="pmid">30425563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-8</page-range>
            <pub-id pub-id-type="pmid">26650429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Nalamachu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morlion</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arjona Ferreira</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.</article-title>
            <source>Pain</source>
            <year>2018</year>
            <month>May</month>
            <volume>159</volume>
            <issue>5</issue>
            <fpage>987</fpage>
            <page-range>987-994</page-range>
            <pub-id pub-id-type="pmid">29419653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cha</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <collab>Constipation Research Group of Korean Society of Neurogastroenterology and Motility</collab>
            </person-group>
            <article-title>Constipation in Patients With Chronic Kidney Disease.</article-title>
            <source>J Neurogastroenterol Motil</source>
            <year>2023</year>
            <month>Oct</month>
            <day>30</day>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-435</page-range>
            <pub-id pub-id-type="pmid">37814433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johanson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Review of the treatment options for chronic constipation.</article-title>
            <source>MedGenMed</source>
            <year>2007</year>
            <month>May</month>
            <day>02</day>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">17955081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ehrenpreis</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Breno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wexner</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Zaitman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Secrest</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-6</page-range>
            <pub-id pub-id-type="pmid">9649012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xing</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Soffer</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of laxatives.</article-title>
            <source>Dis Colon Rectum</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>1201</fpage>
            <page-range>1201-9</page-range>
            <pub-id pub-id-type="pmid">11535863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizwan</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nei</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>e41422</fpage>
            <pub-id pub-id-type="pmid">37546147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Toh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Brayne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sha</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.</article-title>
            <source>Neurology</source>
            <year>2023</year>
            <month>Apr</month>
            <day>18</day>
            <volume>100</volume>
            <issue>16</issue>
            <fpage>e1702</fpage>
            <page-range>e1702-e1711</page-range>
            <pub-id pub-id-type="pmid">36813729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellaturay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ewan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis).</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>670</fpage>
            <page-range>670-675</page-range>
            <pub-id pub-id-type="pmid">33011299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Di Palma</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Medical treatment of constipation.</article-title>
            <source>Clin Colon Rectal Surg</source>
            <year>2005</year>
            <month>May</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-80</page-range>
            <pub-id pub-id-type="pmid">20011345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuster</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Kosar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kamrul</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Constipation in older adults: stepwise approach to keep things moving.</article-title>
            <source>Can Fam Physician</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-8</page-range>
            <pub-id pub-id-type="pmid">25676646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madia</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Messore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saccoliti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tudino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Leo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Vita</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bortolami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scipione</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pindinello</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Costi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Santo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tegaserod for the Treatment of Irritable Bowel Syndrome.</article-title>
            <source>Antiinflamm Antiallergy Agents Med Chem</source>
            <year>2020</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>342</fpage>
            <page-range>342-369</page-range>
            <pub-id pub-id-type="pmid">31518227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijayvargiya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of prucalopride in adults with chronic idiopathic constipation.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>579</fpage>
            <page-range>579-589</page-range>
            <pub-id pub-id-type="pmid">31096799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambizas</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ginzburg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lubiprostone: a chloride channel activator for treatment of chronic constipation.</article-title>
            <source>Ann Pharmacother</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>957</fpage>
            <page-range>957-64</page-range>
            <pub-id pub-id-type="pmid">17519292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamuda</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mazzola</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.</article-title>
            <source>P T</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>207</fpage>
            <page-range>207-232</page-range>
            <pub-id pub-id-type="pmid">29622940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Sandle</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Complications of laxative abuse.</article-title>
            <source>Annu Rev Med</source>
            <year>1996</year>
            <volume>47</volume>
            <fpage>127</fpage>
            <page-range>127-34</page-range>
            <pub-id pub-id-type="pmid">8712767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roerig</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steffen</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zunker</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Laxative abuse: epidemiology, diagnosis and management.</article-title>
            <source>Drugs</source>
            <year>2010</year>
            <month>Aug</month>
            <day>20</day>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>1487</fpage>
            <page-range>1487-503</page-range>
            <pub-id pub-id-type="pmid">20687617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oster</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Materson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Laxative abuse syndrome.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1980</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>451</fpage>
            <page-range>451-8</page-range>
            <pub-id pub-id-type="pmid">7234824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Copeland</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Renal failure associated with laxative abuse.</article-title>
            <source>Psychother Psychosom</source>
            <year>1994</year>
            <volume>62</volume>
            <issue>3-4</issue>
            <fpage>200</fpage>
            <page-range>200-2</page-range>
            <pub-id pub-id-type="pmid">7531354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirasawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Erratum to: Diuretics-assisted treatment of chronic laxative abuse.</article-title>
            <source>CEN Case Rep</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-216</page-range>
            <pub-id pub-id-type="pmid">28509204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costilla</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Foxx-Orenstein</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Constipation in adults: diagnosis and management.</article-title>
            <source>Curr Treat Options Gastroenterol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>310</fpage>
            <page-range>310-21</page-range>
            <pub-id pub-id-type="pmid">25015533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24120.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moreman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>"The constipation conundrum": Improving recognition of constipation on a gastroenterology ward.</article-title>
            <source>BMJ Qual Improv Rep</source>
            <year>2016</year>
            <volume>5</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">27752319</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
